On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

NetworkNewsBreaks – BriaCell Therapeutics Corp.’s (TSX-V: BCT) (OTCQB: BCTXF) Lead Product Candidate Highlighted in Frontiers in Immunology Publication

BriaCell Therapeutics (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, recently announced that a manuscript highlighting the company’s lead product candidate, Bria-IMT™, was published in Frontiers in Immunology. The manuscript describes the novel mechanism of action of Bria-IMT™ as well as encouraging clinical results observed in current and … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp.’s (TSX-V: BCT) (OTCQB: BCTXF) Lead Product Candidate Highlighted in Frontiers in Immunology Publication”

BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Raising Investments, Awareness and Enrollment in Clinical Trials

Using a proprietary technology platform in development of immunotherapy treatments to fight cancer Company recently announced proposed investment by leading biotech funds and concurrent non-brokered financing for combined gross proceeds of up to $4.8 million Using social media to raise awareness and expand patient recruitment for Bria-IMT™ clinical trials BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: … Continue reading “BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Raising Investments, Awareness and Enrollment in Clinical Trials”

NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Details Proposed Financing Deals Valued at Up to $4.8M

Immuno-oncology focused biotechnology company BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) recently announced plans to enter into a securities purchase agreement of convertible notes with a leading group of biotech-focused institutional and family office funds for an investment of $800,000. Under the terms of the proposed agreement, the note offering will consist of a five … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Details Proposed Financing Deals Valued at Up to $4.8M”

NetworkNewsAudio – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Interview

About BriaCell Therapeutics Corp. BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. … Continue reading “NetworkNewsAudio – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Interview”

Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment

NetworkNewsWire Editorial Coverage: Personalized treatment for advanced breast cancer is a massive global medical need. According to latest figures from the Centers for Disease Control, in the United States alone more than 41,000 women die from breast cancer each year. Hope is on the horizon, however, as innovative biomedical companies apply their research and technologies … Continue reading “Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment”

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217